Study of GS-4528 in Adults With Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

182

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Solid Tumor
Interventions
BIOLOGICAL

GS-4528

Administered intravenously

DRUG

Zimberelimab

Administered intravenously.

Trial Locations (16)

333

Chang Gung Memorial Hospital Linkuo Branch of the Chang Gung Medical Foundation, Taoyuan District

28040

START MADRID_Hospital Universitario Fundacion Jimenez Diaz - Unidad de Ensayos Fases I, Madrid

28050

START MADRID_HM Sanchinarro-CIOCC-Unidad de Ensayos Fases I, Madrid

31008

Clinica Universidad de Navarra- Unidad Central de Ensayos Clinicos, Pamplona

40705

Taichung Veterans General Hospital, Taichung

98109

The University of Washington/FHCC, Seattle

100229

National Taiwan University Hospital, Taipei

K1H 8L6

The Ottawa Hospital, Ottawa

M5G 1Z5

University Health Network, Princess Margaret Cancer Centre, Toronto

05505

Asan Medical Center, Seoul

06273

Severance Hospital, Yonsei University Health Systems, Seoul

06351

Samsung Medical Center, Seoul

08023

NEXT Oncology-Hospital Quironsalud Barcelona - Unidad de Ensayos Fase 1, Barcelona

08035

Hospital Universitari Vall D'Hebron- Oncology Service, Barcelona

E1 1FR

St Bartholomew's Hospital, London

SM2 5PT

The Royal Marsden NHS Foundation Trust, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY